Bayer Subsidiary Gets Fast-track Status for Parkinson's Treatment in U.S.

By David Sachs


A Bayer-owned drug developer received special fast-track status from U.S. regulators for its Parkinson's disease treatment following positive phase-1 trials.

The German...

Related Keywords

Germany ,German ,Christian Rommel ,David Sachs ,Drug Administration ,Bluerock Therapeutic ,Regenerative Medicine Advanced Therapy ,Dow Jones ,